Novartis financial results Q3 2024

Novartis Financial Results – Q3 2024

Novartis announced the company’s financial results for the third quarter of 2024.

Learn more
Shanelle Gabriel spending time with her father in New York

Novartis in Society Integrated Report 2023

This report covers our business, strategy, and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.
Team meeting

About Us

At Novartis, we are united by a single purpose to reimagine medicine to improve and extend people’s lives.
A highly trained Novartis specialist dresses in full personal protective equipment to work on the radioligand therapy production line

Drug delivery, service delivery, and the future of cancer care

State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.

Read more
Scientist in lab

Beacon of Hope

Novartis is expanding the Beacon of Hope program through new collaborations to address systemic health disparities.
A photo of people in a meeting hall

Contact Us

Find information on our research locations and corporate offices in US.
Meeting in Atrium

Careers

769 million lives touched by our products. Join us.

Latest News

Oct 29, 2024

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Oct 26, 2024

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

Oct 24, 2024

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
View more